- Zacks Small Cap Research•2 months ago
By Grant Zeng, CFA TSX:COT.V On March 17 , 2016, COTI (TSX:COT.V) announced that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would otherwise ...
- Zacks Small Cap Research•4 months ago
Critical Outcome Technologies Inc. (COT.V) is a clinical stage biopharmaceutical Company which is focused on the discovery and development of cancer treatments through targeted therapeutics. In addition to CHEMSAS®, COTI has also developed ROSALIND. ROSALIND is a computer platform for realizing the promise of personalized medicine for cancer patients.
Critical Outcome Technologies Inc.TSXV
|52wk Range||0.20 - 0.90|
|Day's Range||0.66 - 0.69|
|Avg Vol (3m)||162,657|
As of 3:45 PM EDT. Market closed.